Skip to main content

JM, Swan in battery partnership

Johnson Matthey, Thomas Swan and the UK’s Centre for Process Innovation (CPI) have teamed up in the ICE-Batt project. This seeks how to optimise battery technology by using innovative forms of carbon to overcome some of the limitations of lithium-ion batteries, including energy density, power density and low temperature performance.

JM to exit pharma?

In a pre-close trading update for the financial year ended 31 March 2021, Johnson Matthey (JM) CEO Robert MacLeod revealed that: “We have commenced a strategic review of Health, as we continue to focus resources to maximise value for our shareholders”.

Full results will be announced on 27 May but it is known that Health, which offers API custom manufacturing services, controlled substances, catalysts and generics, generated sales of £223 million, about 5% of the total sale. The division’s full-year operating performance is expected to be above the prior year.

JM buys from 3M

Johnson Matthey has acquired the full IP rights to a portfolio of silicon alloy-based anode materials for battery cells from 3M.
Subscribe to Johnson Matthey